Biological Evaluation of Novel Schiff Base Metal Complexes: A Review

Reference

1. Schiff H. Mittheilungen aus dem Universitätslaboratorium in Pisa: Eine neue Reihe organischer Basen. Justus Liebigs Ann Chem. 1864; 131:118–119.
2. Calligaris M, Randaccio L. Structural aspects of Schiff bases and metal complexes. Coord Chem Rev. 1987; 7:385–403.
3. Singh K, Barwa MS, Tyagi P. Synthesis, characterization and biological studies of Co (II), Ni (II), Cu(II) and Zn(II) complexes with bidentate Schiff bases. Eur J Med Chem. 2006; 41:147–153.
4. Tweedy BG. Plant extracts with metal ions as potential antimicrobial agents. Phytopathology. 1964; 55:910–918.
5. Patai S. The Chemistry of the Carbon–Nitrogen Double Bond. New York: Wiley; 1970.
6. Kostova I. Platinum complexes as anticancer agents. Recent Pat Anticancer Drug Discov. 2006; 1:1–22.
7. Layer RW. The chemistry of imines. Chem Rev. 1963; 63:489–510.
8. Dhar DN, Taploo CL. Schiff bases and their applications. J Sci Ind Res. 1982; 41:501–506.
9. Karthikeyan MS et al. Microwave-assisted synthesis of Schiff bases: A green approach. J Chem Sci. 2010; 122:803–809.
10. Nakamoto K. Infrared and Raman Spectra of Inorganic and Coordination Compounds. 6th ed. Wiley; 2009.
11. Lever ABP. Inorganic Electronic Spectroscopy. Elsevier; 1984.
12. Cotton FA, Wilkinson G. Advanced Inorganic Chemistry. 6th ed. Wiley; 1999.
13. Figgis BN, Hitchman MA. Ligand Field Theory and Its Applications. Wiley-VCH; 2000.
14. Silverstein RM, Webster FX. Spectrometric Identification of Organic Compounds. 7th ed. Wiley; 2005.
15. Claridge TDW. High-Resolution NMR Techniques in Organic Chemistry. Elsevier; 2009.
16. Hoffmann E, Stroobant V. Mass Spectrometry: Principles and Applications. Wiley; 2007.
17. Glusker JP, Lewis M, Rossi M. Crystal Structure Analysis for Chemists and Biologists. Wiley; 1994.
18. Earnshaw A. Introduction to Magnetochemistry. Academic Press; 1968.
19. Kostova I, Saso L. Advances in research of Schiff base metal complexes as potent antioxidants. Curr Med Chem. 2013; 20:4609–4632.
20. Singh K et al. Antimicrobial properties of transition metal complexes of Schiff bases. Eur J Med Chem. 2009; 44:1731–1736.
21. Tweedy BG. Chelation theory and antimicrobial activity. Phytopathology. 1964; 55:910–918.
22. Chohan ZH et al. Biological role of metal complexes of Schiff bases. Appl Organomet Chem. 2010; 24:593–600.
23. Guo Z, Sadler PJ. Metals in medicine. Angew Chem Int Ed. 1999; 38:1512–1531.
24. Refat MS et al. Copper (II) complexes as antimicrobial agents. Spectrochim Acta A. 2014; 123:454–466.
25. Dhar S, Lippard SJ. Mitaplatin and platinum complexes in cancer therapy. Proc Natl Acad Sci USA. 2009; 106:22199–22204.
26. Barton JK. DNA binding of metal complexes. Science. 1986; 233:727–734.
27. Trachootham D et al. Targeting cancer cells by ROS-mediated mechanisms. Nat Rev Drug Discov. 2009; 8:579–591.
28. Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol. 2007; 35:495–516.
29. Vermeulen K et al. Cell cycle regulation in cancer. Cell Prolif. 2003; 36:131–149.
30. Alessio E. Bioinorganic medicinal chemistry of ruthenium complexes. Eur J Inorg Chem. 2017;1549–1560.
31. Blois MS. Antioxidant determinations by DPPH method. Nature. 1958; 181:1199–1200.
32. Benzie IF, Strain JJ. Ferric reducing ability of plasma (FRAP) assay. Anal Biochem. 1996; 239:70–76.
33. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Am J Med. 1998; 104:2S–8S.
34. Barnes PJ. Cytokine modulators in inflammation. Nat Rev Drug Discov. 2003; 2:192–204.
35. Mittal M et al. Reactive oxygen species in inflammation. Antioxid Redox Signal. 2014; 20:1126–1167.
36. De Clercq E. Anti-HIV agents. Nat Rev Drug Discov. 2002; 1:13–25.
37. Moradpour D et al. Hepatitis C virus therapy. Nat Rev Drug Discov. 2007; 6:453–463.
38. Zhang L et al. Metal complexes as antiviral agents. Coord Chem Rev. 2020; 414:213260.
39. Soreq H, Seidman S. Acetylcholinesterase inhibitors in Alzheimer’s disease. Nat Rev Neurosci. 2001; 2:294–302.
40. Krajewska B. Urease inhibitors. J Mol Catal B Enzym. 2009; 59:9–21.
41. Lebovitz HE. Alpha-glucosidase inhibitors. Clin Diabetes. 1998; 16:130–135.
42. Copeland RA. Evaluation of Enzyme Inhibitors in Drug Discovery. Wiley; 2005.
43. Mishra AP, Pandey LR. Structural and biological aspects of Schiff base metal complexes. Indian J Chem. 2005;44A:94–100.
44. Guo Z, Sadler PJ. Metals in medicine: Design and mechanism of action. Angew Chem Int Ed. 1999; 38:1512–1531.
45. Lever ABP. Coordination geometry and ligand field effects. Inorg Chem. 1990; 29:1271–1285.
46. Hamid MHSA et al. Substituent effects in Schiff base complexes and biological activity. Eur J Med Chem. 2012; 57:302–313.
47. Calligaris M. Denticity and stability of Schiff base complexes. Coord Chem Rev. 2004; 248:351–375.
48. Tweedy BG. Chelation theory and biological activity. Phytopathology. 1964; 55:910–918.
49. Refat MS et al. Copper (II) Schiff base complexes and anticancer evaluation. Spectrochim Acta A. 2014; 123:454–466.
50. Vallee BL, Auld DS. Zinc coordination in enzymes. Biochemistry. 1990; 29:5647–5659.
51. Barton JK, Lippard SJ. DNA interactions of metal complexes. Biochemistry. 1979; 18:2661–2668.
52. Kostova I. Synthetic and natural coumarins as cytotoxic agents. Curr Med Chem. 2005; 12:143–159.
53. Tweedy BG. Chelation theory and antimicrobial activity. Phytopathology. 1964; 55:910–918.
54. Chohan ZH et al. Metal-based antibacterial and antifungal agents. Appl Organomet Chem. 2010; 24:593–600.
55. Guo Z, Sadler PJ. Metals in medicine. Angew Chem Int Ed. 1999; 38:1512–1531.
56. Barton JK. Metal complexes and DNA binding. Science. 1986; 233:727–734.
57. Neidle S. DNA minor-groove recognition by small molecules. Nat Prod Rep. 2001; 18:291–309.
58. Sigman DS et al. Oxidative DNA cleavage by metal complexes. Chem Rev. 1993; 93:2295–2316.
59. Jackson SP, Bartek J. The DNA damage response in human biology. Nature. 2009; 461:1071–1078.
60. Trachootham D et al. Targeting cancer cells by ROS-mediated mechanisms. Nat Rev Drug Discov. 2009; 8:579–591.
61. Simon HU et al. Role of reactive oxygen species in apoptosis. Apoptosis. 2000; 5:415–418.
62. Gorrini C et al. Modulation of oxidative stress in cancer therapy. Nat Rev Drug Discov. 2013; 12:931–947.
63. Jaouen G, Metzler-Nolte N. Medicinal organometallic chemistry. Chem Soc Rev. 2010; 39:1167–1188.
64. Valko M et al. Metals, toxicity and oxidative stress. Curr Med Chem. 2005; 12:1161–1208.
65. Mosmann T. Rapid colorimetric assay for cellular growth and survival (MTT assay). J Immunol Methods. 1983; 65:55–63.
66. Bézivin C et al. Selectivity index in cytotoxicity evaluation. Phytomedicine. 2003; 10:1–6.
67. Olson H et al. Concordance of toxicity of pharmaceuticals in animals and humans. Regul Toxicol Pharmacol. 2000; 32:56–67.
68. Gad SC. Animal Models in Toxicology. 2nd ed. CRC Press; 2007.
69. Hartinger CG, Dyson PJ. Bioorganometallic chemistry. Chem Soc Rev. 2009; 38:391–401.
70. Ndagi U, Mhlongo N, Soliman ME. Metal complexes in cancer therapy – an update. Drug Des Devel Ther. 2017; 11:599–616.
71. Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs. Chem Rev. 2016; 116:3436–3486.
72. Alessio E. Thirty years of ruthenium anticancer complexes. Eur J Inorg Chem. 2017;1549–1560.
73. Rai M et al. Metal-based antimicrobial agents: A new era. Appl Microbiol Biotechnol. 2012; 94:287–298.
74. Supuran CT. Carbonic anhydrase inhibitors in drug design. Nat Rev Drug Discov. 2008; 7:168–181.
75. Hartinger CG, Dyson PJ. Bioorganometallic chemistry in drug development. Chem Soc Rev. 2009; 38:391–401.
76. Bertrand B, Casini A. A golden future in medicinal inorganic chemistry. Dalton Trans. 2014; 43:4209–4219.
77. Peer D et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007; 2:751–760.
78. Anastas PT, Warner JC. Green Chemistry: Theory and Practice. Oxford University Press; 1998.
79. Mjos KD, Orvig C. Metallodrugs in medicinal inorganic chemistry. Chem Rev. 2014; 114:4540–4563.
80. Kostova I. Synthetic and natural coumarins as cytotoxic agents. Curr Med Chem. 2005; 12:143–159.
81. Meng XY et al. Molecular docking: A powerful approach for drug discovery. Curr Comput Aided Drug Des. 2011; 7:146–157.
82. Lionta E et al. Structure-based virtual screening for drug discovery. Curr Top Med Chem. 2014; 14:1923–1938.
83. Barry NPE, Sadler PJ. Exploration of metal-based drug design. Chem Commun. 2013; 49:5106–5131.
84. Patra M, Gasser G. The medicinal chemistry of organometallic compounds. Nat Rev Chem. 2017; 1:0066.
85. Hartinger CG et al. From bench to bedside: The future of metal-based drugs. J Inorg Biochem. 2013; 118:2–15.